Pipeline Overview

Tarveda’s pipeline exemplifies the company’s Pentarin® platform that creates novel treatments designed to improve the effectiveness of cancer therapies for solid tumors.

Tarveda’s lead Pentarin clinical drug candidate, PEN‑221, targets the somatostatin receptor 2 (SSTR2) for treatment of patients with tumors including neuroendocrine, small cell lung and other cancers that express SSTR2. PEN-221 comprises a peptide, which is highly selective for SSTR2 conjugated to the potent cytotoxic DM1 through a tuned cleavable linker. PEN-221 is in a Phase 1/2a clinical trial.

Tarveda is also advancing its HSP90 drug conjugate platform with lead drug candidate PEN‑866, which is a miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90), and is linked to the payload SN-38. PEN-866, is designed to treat patients with solid tumors including those with colorectal, small cell lung, and pancreatic cancers and sarcoma. PEN-866 is currently being evaluated in a Phase 1/2a clinical trial. 

Tarveda is advancing our pipeline with a focus on both cell surface and intracellular targets in solid tumors and has generated data demonstrating that Pentarins may be effective as a new and innovative class of drug conjugates with ability to effectively penetrate into tumor tissue.